Emergent Biosolutions (EBS) Stock Price, News & Analysis

Company Overview

Emergent BioSolutions Inc. is a global life sciences company dedicated to the development, manufacture and delivery of vaccines and antibody therapies that address public health threats. The company’s portfolio encompasses a range of biodefense and infectious disease countermeasures, including the U.S.‐licensed anthrax vaccine BioThrax® and the smallpox vaccine ACAM2000®. In addition to its proprietary products, Emergent offers contract development and manufacturing services for governments and commercial partners, with specialized capabilities in large‐scale biologics production.

Since its founding in 1998 and subsequent initial public offering in 2006, Emergent has expanded through strategic acquisitions such as Cangene Corporation and Adapt Pharma, broadening its product offerings to include treatments for opioid overdose and other critical care needs. The company’s Infectious Disease segment has introduced naloxone nasal spray under the Narcan® brand, demonstrating its commitment to addressing both biodefense and emerging public health crises. Emergent’s vaccine development pipeline also targets diseases such as Zika and chikungunya, reflecting its focus on readiness for future outbreaks.

Headquartered in Gaithersburg, Maryland, Emergent BioSolutions serves customers across North America, Europe and the Asia-Pacific region, with key government clients including the U.S. Department of Health and Human Services and various defence agencies. Its manufacturing facilities, located in the United States and Puerto Rico, are designed to meet stringent regulatory and security standards required for national stockpile products. The company has also forged partnerships with global health organizations to support vaccine access in emerging markets.

Under the leadership of President and Chief Executive Officer Robert G. Kramer Jr., Emergent’s executive team brings deep expertise in biotechnology, government contracting and large‐scale manufacturing. Guided by a board of directors with backgrounds in public health, finance and regulatory affairs, the company continues to invest in research and development, facility expansion and strategic collaborations to strengthen global preparedness against current and future health threats.

Key Stats

• Today's Range: $7.18 to $7.41
• 50-Day Range: $4.74 to $7.34
• 52-Week Range: $4.02 to $15.10
• Volume: 1.05 million shs
• Average Volume: 1.70 million shs
• Market Capitalization: $398.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.33
• Consensus Rating: Buy

Emergent Biosolutions Stock Analysis - MarketRank™

Emergent Biosolutions scored higher than 85% of companies evaluated by MarketBeat, and ranked 173rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Emergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Emergent Biosolutions has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Emergent Biosolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Emergent Biosolutions is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Emergent Biosolutions is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Emergent Biosolutions has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.28% of the float of Emergent Biosolutions has been sold short.

Short Interest Ratio / Days to Cover

Emergent Biosolutions has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Emergent Biosolutions has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Emergent Biosolutions does not currently pay a dividend.

Dividend Growth

Emergent Biosolutions does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.40

Percentage of Shares Shorted

19.28% of the float of Emergent Biosolutions has been sold short.

Short Interest Ratio / Days to Cover

Emergent Biosolutions has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Emergent Biosolutions has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

Emergent Biosolutions has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Emergent Biosolutions this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,417.00 in company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Emergent Biosolutions is held by insiders.

Percentage Held by Institutions

78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EBS Stock Analysis - Frequently Asked Questions

How have EBS shares performed this year?

Emergent Biosolutions' stock was trading at $9.56 at the start of the year. Since then, EBS shares have decreased by 23.2% and is now trading at $7.34.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc. (NYSE:EBS) released its earnings results on Wednesday, May, 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.22. The biopharmaceutical company had revenue of $222.20 million for the quarter, compared to analyst estimates of $218.50 million. Emergent Biosolutions had a negative trailing twelve-month return on equity of 0.52% and a negative net margin of 13.63%.
Read the conference call transcript.

Is Emergent Biosolutions doing a stock buyback?

Emergent Biosolutions' board approved a share buyback program on Monday, March 31st 2025, which authorizes the company to repurchase $50,000,000 in shares, according to EventVestor. This means that the company could buy up to 19% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its shares are undervalued.

Who are Emergent Biosolutions' major shareholders?

Top institutional investors of Emergent Biosolutions include Assenagon Asset Management S.A. (0.57%), Kingstone Capital Partners Texas LLC (0.07%) and Harbor Capital Advisors Inc. (0.06%). Insiders that own company stock include Neal Franklin Fowler, Keith Katkin, Kathryn C Zoon and Ronald Richard.
View institutional ownership trends.

How do I buy shares of Emergent Biosolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:EBS
• CIK: 1367644
• Web: www.emergentbiosolutions.com
• Phone: (240) 631-3200
• Fax: 301-795-1899
• Employees: 2,420
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Emergent Biosolutions: $14.33
• High Price Target: $16.00
• Low Price Target: $12.00
• Potential Upside/Downside: +95.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.60 million
• Net Margins: -13.63%
• Pretax Margin: -6.45%
• Return on Equity: -0.52%
• Return on Assets: -0.17%

Debt

• Debt-to-Equity Ratio: 1.20
• Current Ratio: 6.32
• Quick Ratio: 3.51

Sales & Book Value

• Annual Sales: $1.04 billion
• Price / Sales: 0.38
• Cash Flow: $1.92 per share
• Price / Cash Flow: 3.82
• Book Value: $8.91 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 54,280,000
• Free Float: 53,627,000
• Market Cap: $398.42 million
• Optionable: Optionable
• Beta: 2.09